Yoon Soo Shin

Yoon Soo Shin

Auto-generated profile, based on publicly available information

Yoon Soo Shin

Division of Nephrology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
YLYu Ho Lee
Yu Ho Lee
YSYoon Soo Shin
Yoon Soo Shin
SLSo-Young Lee
So-Young Lee
YKYang Gyun Kim
Yang Gyun Kim
SLSang Ho Lee
Sang Ho Lee
HJHye Yun Jeong
Hye Yun Jeong
Background: Online hemodiafiltration (OL-HDF) offers considerable advantages in clearance of molecules of various sizes. However, evidence of clinical effects of OL-HDF is scarce in Korea. In this study, we investigated changes in laboratory values over more than 12 months after switching to OL-HDF. Methods: Adult patients with end-stage renal disease undergoing hemodialysis (HD) were prospectively enrolled in a K-cohort (CRIS no. KCT0003281) from 6 tertiary hospitals in South Korea. We recruited 435 patients, 339 of whom were on HD at enrollment. One hundred eighty-two patients were followed for more than 24 months. Among them, 44 were switched to OL-HDF for more than 12 months without conversion to HD. We used a paired t test to compare baseline and 24-month follow-up results. Results: The mean age of the subjects was 61.2 +/- 12.2 years, and 62.6% were male. The baseline hemoglobin level was not significantly different between HD and OL-HDF group (10.61 +/- 1.15 vs. 10.46 +/- 1.03 g/dL, P = 0.437). However, the baseline serum protein and albumin levels were significantly lower in the OL-HDF group (6.82 +/- 0.49 vs. 6.59 +/- 0.48 g/dL, P= 0.006; 3.93 +/- 0.28 vs. 3.73 +/- 0.29 g/dL, P< 0.001). In patients switched to OL-HDF, levels of hemoglobin and serum albumin significantly increased (10.46 +/- 1.03 vs. 11.08 +/- 0.82 g/dL, P= 0.001; 3.73 +/- 0.29 vs. 3.87 +/- 0.30 g/dL, P = 0.001). The normalized protein catabolic rate decreased after 24 months, but the change was not significant (1.07 +/- 0.25 vs. 1.03 +/- 0.21 g/kg/day, P = 0.433). Although the dose of erythropoiesis-stimulating agent was lower in patients who converted to HDF, it was not significantly different (-115.7 +/- 189.7 vs. -170.5 +/- 257.1 P = 0.206). Conclusion: OL-HDF treatment over more than 12 months was associated with no harmful effects on anemia and nutritional status.